Thursday, August 18, 2005


Ablynx is a biotech startup exploiting naturally occuring camel antibodies that consist solely of heavy chains, and therefore offer several potential advantages as therapeutics. Scientific American has a quality story on the sci-biz of these "NANOBODIES". The company was launched through the Flanders Institute for Biotechnology in Belgium. They seem to have a pretty slick research setup aimed at launching new biotech.